Abstract

Hepatocellular carcinoma (HCC) is, globally, one of the most prevalent and deadly human cancers; despite curative surgical resection, its high recurrence rate after surgery remains a large threat, resulting in poor patient survival. The hepatitis B virus (HBV) pre-S2 mutant that harbors deletions spanning the pre-S2 gene segment has emerged as an important oncoprotein for HCC development and a valuable prognostic biomarker for HCC recurrence; however, its relationship with clinicopathological factors is largely unexplored. In this study, the correlation of the deletion spanning the pre-S2 gene segment with clinicopathological factors and the association of such correlation with HCC recurrence after curative surgical resection were examined in HBV-related HCC patients. Inverse correlation between serum albumin level and the deletion spanning the pre-S2 gene segment was identified. HCC patients with the presence of the deletion spanning the pre-S2 gene segment and a low serum albumin level were associated with higher HCC recurrence than patients with either factor alone or neither factor were. Moreover, a combination of the serum albumin level and the deletion spanning the pre-S2 gene segment exhibited better performance than that of either factor alone in predicting HCC recurrence. Collectively, this study shows an association of low serum albumin level with pre-S2 mutant-positive HCC patients, and validates the prognostic value of this association in identifying patients with higher HCC recurrence after curative surgical resection.

Highlights

  • Liver transplantation and surgical resection are available as potentially curative treatments for Hepatocellular carcinoma (HCC), the former is limited by a scarcity of donor livers, and the latter is challenged by high HCC recurrence after surgery, leading to poor patient survival [3,4]

  • Plasma samples were retrospectively collected from 75 hepatitis B virus (HBV)-related HCC patients on the day of curative surgical resection that they received at China Medical University

  • Pre-S2 mutant in the blood of HBV-related HCC patients was detected with a nextgeneration sequencing (NGS)-based method as described [25]

Read more

Summary

Introduction

Hepatocellular carcinoma (HCC) is the dominant type of liver cancer and, globally, is the sixth most frequent and third most lethal human cancer, causing up to 800,000 deaths every year [1,2]. Liver transplantation and surgical resection are available as potentially curative treatments for HCC, the former is limited by a scarcity of donor livers, and the latter is challenged by high HCC recurrence after surgery, leading to poor patient survival [3,4]. The high drug resistance and genetic heterogeneity of HCC limit the survival benefits of chemotherapy and molecular targeted therapy in HCC patients, respectively [5,6]. It is still a key goal to discover valuable biomarkers and therapeutics of HCC development and recurrence for early detection and better management to improve patient outcomes

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.